NasdaqGM:ZLABBiotechs
Zai Lab Weighs New Pipeline Data And KarXT Launch Against Revenue Pressures
Zai Lab (NasdaqGM:ZLAB) reported new clinical data from its global oncology and immunology pipeline, including intracranial response data for zoci in small cell lung cancer.
The company is preparing to launch KarXT in China for schizophrenia in the next quarter.
Management highlighted these pipeline and launch updates while also flagging near term revenue pressure.
Zai Lab focuses on developing and commercializing medicines in oncology and immunology, as well as central nervous system...